-
Safety Signals Force Enanta To Stop EDP-721 HBV Program
Friday, November 19, 2021 - 8:15am | 195Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer. The move follows safety signals observed in the single ascending dose part of a Phase 1 study in healthy volunteers. "Despite the...
-
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
Monday, September 27, 2021 - 9:53am | 318Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surface antigen (HBsAg) expression, and prevent viral rebound of hepatitis B virus (HBV...
-
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Tuesday, July 6, 2021 - 10:19am | 253Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The...
-
Vir Biotech's HBV Candidates Show Positive Safety Profiles
Friday, June 25, 2021 - 3:02pm | 229Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. The results were presented at the European Association for the Study of the Liver...
-
Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany
Thursday, May 27, 2021 - 8:47am | 147Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021. Financial terms were not...
-
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
Wednesday, May 12, 2021 - 10:15am | 319VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases. The study was designed to compare the immunogenicity and...
-
Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA
Friday, May 7, 2021 - 9:58am | 328Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC). The data...
-
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
Wednesday, April 21, 2021 - 8:50am | 299Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment...
-
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
Friday, February 26, 2021 - 12:52pm | 305Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (...
-
Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug
Thursday, October 4, 2018 - 10:12am | 382Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) develops medicines to treat intractable diseases. The company’s therapies trigger the RNA interference to alter target genes, as a natural process of gene silencing. What Happened Arrowhead announced entrance into a $3.7-billion license and...
-
Exclusive: Sinovac IR Director Explains Massive Revenue Opportunity
Friday, June 13, 2014 - 10:46am | 459In an exclusive interview with Benzinga, director of Investor Relations, Helen Yang, discussed Sinovac’s (NASDAQ: SVA) future opportunities. Sinovac is Chinese biopharmaceutical company which produces, among others, a hepatitis A and B vaccine and is currently preparing to commercialize...